Mepolizumab in Chronic Obstructive Pulmonary Diseases (COPD) With Eosinophilic Bronchitis

PHASE3CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

August 31, 2015

Study Completion Date

September 30, 2015

Conditions
Chronic Obstructive Pulmonary DiseasesChronic Airways LimitationBronchitis
Interventions
DRUG

Mepolizumab

This is an anti IL-5 which is given once a month intravenously at the dose of 750 mg.

DRUG

placebo

The placebo will consist of 100 mL normal saline solution (0.9%, 154 mmol/L sodium chloride).

Trial Locations (1)

L8N 4A6

Firestone Institute of Respiratory Health, St Joseph's Hospital, Hamilton

All Listed Sponsors
lead

McMaster University

OTHER

NCT01463644 - Mepolizumab in Chronic Obstructive Pulmonary Diseases (COPD) With Eosinophilic Bronchitis | Biotech Hunter | Biotech Hunter